The biological activities of the novel echinocandin-like lipopeptides, FR209602, FR209603 and FR209604, were evaluated. These compounds showed antifungal activity against Candida albicans and Aspergillus fumigatus attributed to inhibition of 1,3-bglucan synthesis. The minimum effective concentrations of these compounds against C. albicans and A. fumigatus ranged from 0.02 to 0.04 m g/ml by microbroth dilution assay, and the IC 50 values on C. albicans 1,3-b -glucan synthase were 0.49, 0.64 and 0.72 m g/ml, respectively. FR209602 and FR209603 showed good efficacy by subcutaneous injection against C. albicans in a murine systemic infection model, with ED 50 values of 2.0 and 1.9 mg/kg, respectively.
Introduction
Life-threatening infections caused by Candida albicans and Aspergillus fumigatus have been increasing in prevalence [1] . Antifungal therapies, however, are currently limited to a small number of compounds. Toxicity is an issue with treatments based on amphotericin B [2] and resistance is beginning to emerge as a problem with the safer but fungistatic azoles [3] . Therefore, new, safe and effective therapeutic agents are highly desirable for the treatment of infections caused by Candida albicans and A. fumigatus.
In the previous paper [4] , we described the novel antifungal lipopeptides, FR209602, FR209603 and FR209604, produced by Coleophoma crateriformis No. 738. These compounds have potent antifungal activity against Candida albicans and A. fumigatus attributed to inhibition of 1,3-b -glucan synthesis. Fungal cell wall components, especially 1,3-b-glucan, are promising targets for antifungals, because this is essential to fungi and absent from mammalian cells [5] . In recent years, the new antifungal, micafungin [6ϳ8] and caspofungin [9] , which belong to the echinocandin-like family of lipopeptides, have been successfully launched as antifungal drugs.
In this paper, we describe the in vitro and in vivo antifungal activities of the newly isolated lipopeptides, FR209602, FR209603 and FR209604.
Materials and Methods

Compound
FR901379 was isolated from the culture broth of Coleophoma empetri F-11899 which is a strain in the Fujisawa culture collection [10, 11] .
In Vitro Antifungal Activity Antifungal activity was measured by the micro-broth dilution method in 96-well culture plates employing yeast nitrogen base -dextrose (YNBD) medium. Candida albicans A. fumigatus FP1305, a strain from the Fujisawa culture collection, was cultured on YM agar slant for 7 days. The spores were harvested in sterile saline, and filtered through gauze. Finally, the fungal cells or spores were resuspended in yeast nitrogen base -dextrose medium for inoculation. Test compounds were diluted serially two fold with YNBD. The test microorganism was inoculated to each well to yield 1ϫ10 4 cfu/well in 100 ml. The plates were incubated for 20 hours at 37°C (Candida albicans FP633 and A. fumigatus FP1305) or 48 hours at 37°C (Cryptococcus neoformans YC203). Minimum effective concentration (MEC) was determined by microscopic observation.
Membrane Fraction Preparation of Candida albicans
Membrane fraction preparation from Candida albicans was conducted according to the method described by Sawistowska-Schröder et al. [12] with some modifications. Briefly, yeast cells of Candida albicans FP633 were grown to logarithmic phase (absorbance at 660 nm; 0.42) in YNBD medium at 30°C with shaking. The cells were harvested by centrifugation, washed and suspended in icecold buffer A (50 mM Tris-HCl (pH 7.5), 1.0 mM bmercaptoethanol, 1.0 M sucrose and 25 m M GTP). The cells were sonicated with 0.4 mm i.d. glass beads using a sonicator. The glass beads were then washed with ice-cold buffer B (buffer A without sucrose), and the cell debris were removed by centrifugation. The supernatant fluids were centrifuged at 100,000ϫg for 45 minutes at 4°C. The pellet was washed with buffer B, resuspended in buffer C (buffer B -glycerol, 2 : 1) at 10 mg protein/ml and stored at Ϫ80°C as a source of particulate enzyme for glucan synthase assay.
Glucan Synthase Assay
The assay procedure for Candida albicans glucan synthase was conducted according to the method described by Sawistowska-Schröder et al. [12] with some modifications. Two and a half ml of test compound solution or vehicle was incubated with 25 ml of reaction mixture (50 mM Tris-HCl (pH 8.0), 0.8% BSA, 0.1 mM GTP, 0.1% CHAPS, 0.05% Tween80 and the particulate enzyme (40 mg protein)) for 15 minutes at room temperature. After incubation, 25 m l of UDP-[U-
14 C]glucose (0.35 mCi/ml, 1.0 mM) was added to the reaction vessel to react for 60 minutes at room temperature. The reaction was terminated by addition of 100 m l ice-cold 10% trichloroacetic acid (TCA) and allowed to stand on ice. The resultant precipitate was dissolved with 1 N NaOH. After neutralization, radioactivity was counted with a toluene scintillator.
In Vivo Antifungal Activities of FR209602 and FR209603 against Candida albicans in a Murine Infection Model
The in vivo anti-Candida activities were evaluated in a murine model of systemic infection using Candida albicans FP633. The inoculum was prepared from a threeday old culture of YM agar slant. ICR mice (female, four weeks old), were intravenously injected with 1ϫ10 6 cells of the yeast. Five mice were used in each group. Test compounds were dissolved in saline and administered subcutaneously one hour after challenge and once a day for three consecutive days. The ED 50 value was determined on the day when all control mice (vehicle only) died. Table 1 shows the antifungal activities of FR20902, FR209603 and FR209604. They showed almost equivalent activities to FR901379 against Candida albicans FP633 and A. fumigatus FP1305. These compounds were also inactive against Cryptococcus neoformans as was FR901379. With all of these compounds, hyphal morphological changes were observed in A. fumigatus, i.e. hyphae abnormally grown, shortened, stunted and highly branched with bipolar or vesicular tips, swollen germ tubes and frequent balloon-like cells (data not shown). These morphological changes were characteristic of the inhibition of 1,3-b -glucan synthesis. Table 2 shows the inhibitory activities of these compounds on b -1,3-glucan synthase derived from Candida albicans FP633. Significant inhibition of b-1,3-glucan synthase was observed in all of these compounds, which was consistent with the in vitro antifungal activities of these compounds.
Results
In Vitro Activities of FR209602, FR209603 and FR209604
In Vivo Antifungal Activities of FR209602 and FR209603 against Candida albicans in a Murine Infection Model
In vivo antifungal activities of FR209602 and FR209603
against Candida albicans in a murine infection model were evaluated, and compared to that of FR901379. Both FR209602 and FR209603 significantly prolonged the survival of infected mice by subcutaneously administration with ED 50 values of 2.0 mg/kg and 1.9 mg/kg, respectively (Table 3) . These efficacies were almost equivalent to that of FR901379. Survival curves for the in vivo systemic infection model are shown in Fig. 2 .
Discussion
In this paper, we have presented in vitro and in vivo activities of novel antifungal lipopeptides, FR209602, infection model. These compounds have similar structures to FR901379, the points of difference being the amino acid constituents of the cyclic peptide portion of their structures. It is known that amino acid composition affects both the antifungal spectrum as well as the chemical stability of lipopeptides. FR209602-4 could therefore provide a new direction for developing the next generation of antifungal agents. 
